Journal
DRUG DEVELOPMENT RESEARCH
Volume 83, Issue 1, Pages 16-54Publisher
WILEY
DOI: 10.1002/ddr.21895
Keywords
anti-viral agent; COVID-19; small molecules
Categories
Funding
- Hangzhou 115 overseas intelligence program [2020C001]
- Hangzhou Normal University startup fund [4125C5021920419]
- Hangzhou Normal University, School of Medicine Teaching Reform Fund [4125b30100112]
- National Natural Science Foundation of China [81730108, 81803340, 81973635, 82073686]
Ask authors/readers for more resources
This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress, aiming to provide researchers with information to accelerate the research programs in searching effective small molecule therapy for treatment of COVID-19.
The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
